Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

The Mechanism Underlying Lenalidomide-Induced Thrombosis Susceptibility

Panpan Li, Bei Xu, Jiadai Xu, Yawen Wang, Yanyan Xu, Chen Chen, Peng Liu

Blood (2023) 142 (Supplement 1): 6505.

https://doi.org/10.1182/blood-2023-185515

Published: 2023

Journal Articles

Clinical Implication of Minimal Residual Disease By Multiparameter Flow Cytometry in Light Chain Amyloidosis

Tianhong Xu, Jing Li, Yang Yang, Wenjing Wang, Pu Wang, Chenqi Yu, Peng Liu

Blood (2023) 142 (Supplement 1): 6770.

https://doi.org/10.1182/blood-2023-184754

Published: 2023

Journal Articles

The China Monoclonal Gammopathy Screening Project in First-Degree Relatives of Patients with Multiple Myeloma (CHAPERONE) –a Multicenter Screening Study

Jing Li, Peng Liu

Blood (2023) 142 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2023-187944

Published: 2023

Journal Articles

Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma

Jiadai Xu, Lu-Ya Cheng, Yang Ke, Yi-An Zhang, Li-Juan Cui, Hui Xiao, Yue-Xin Cheng, Peng Liu

Blood (2023) 142 (Supplement 1): 6146.

https://doi.org/10.1182/blood-2023-181381

Published: 2023

Journal Articles

Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis

Chen Chen, Chenqi Yu, Jing Li, Weiguang Wang, Zhimei Wang, Lu-Ya Cheng, Fei-fei Chen, Jiadai Xu, Tianhong Xu, Yang Yang, Wenjing Wang, Pu Wang, Peng Liu

Blood (2023) 142 (Supplement 1): 6745.

https://doi.org/10.1182/blood-2023-186600

Published: 2023

Journal Articles

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Yian Zhang, Ling Yuan, Jingli Zhuang, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Peng Liu

Blood (2023) 142 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2023-185411

Published: 2023

Journal Articles

Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

Yuhong Ren, Jingli Zhuang, Ling Yuan, Lili Ji, Yang Ke, Peng Liu

Blood (2023) 142 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2023-186170

Published: 2023

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Austin Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre De Fontbrune, Antonio M Risitano, Jong-Wook Lee

Blood (2023) 142 (Supplement 1): 576.

https://doi.org/10.1182/blood-2023-189863

Published: 2023

Journal Articles

IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Manner

Jiadai Xu, Peng Liu

Blood (2023) 142 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2023-185888

Published: 2023

Journal Articles

A Comparative Study of Clinical Characteristics, Cytogenetic Abnormalities and Outcomes Among Multiple Myeloma, Primary Light-Chain Amyloidosis and Multiple Myeloma with Concurrent AL Amyloidosis

Chenqi Yu, Jing Li, Tianhong Xu, Wenjing Wang, Pu Wang, Yang Yang, Peng Liu

Blood (2023) 142 (Supplement 1): 2032.

https://doi.org/10.1182/blood-2023-188350

Published: 2023

Journal Articles

Genomic Determinants of Hematopoietic Progenitor Sensitivity to Innate Immune Signaling

Vu L. Tran, Peng Liu, Alexandra A. Soukup, Audrey Kopp, Bjorn M. Schoff, Ashley E. Mattina, Mabel M. Jung, Marjorie Brand, Kirby D. Johnson, Emery H. Bresnick

Blood (2023) 142 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2023-186320

Published: 2023

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Exclusive Benefits of Sustained MRD-Negative in High-Risk Multiple Myeloma

Liang Ren, Tianhong Xu, Wenjing Wang, Yang Yang, Yawen Wang, Aziguli Maihemaiti, Tianwei Lan, Panpan Li, Chi Zhou, Pu Wang, Peng Liu

Blood (2023) 142 (Supplement 1): 6663.

https://doi.org/10.1182/blood-2023-172450

Published: 2023

Journal Articles

Deletion of the Artery Specific Enhancer Promotes B Cell and Impairs T Cell Development from the Hemogenic Endothelium

Saritha S. D'souza, Akhilesh Kumar, Yoon Jung Choi, Samuel Dettle, Isla Emmen, Portia Smith, Divine M. Sedzro, Ho Sun Jung, Peng Liu, Igor Slukvin

Blood (2023) 142 (Supplement 1): 1299.

https://doi.org/10.1182/blood-2023-174748

Published: 2023

Journal Articles

Short-Term Follow-up of Blinatumomab in Children with B-Cell Precursor Acute Lymphoblastic Leukemia：Study of a Single Center from China

Wenyu Yang, Xiaolan Li, Li-Peng Liu, Yang Wan, Tianfeng Liu, Bei-bei Zhao, Min Ruan, Benquan Qi, Xia Chen, Fang Liu, Yuanyuan Ren, Li Zhang, Yao Zou, Yumei Chen, Xiaojuan Chen, Ye Guo, Xiaofan Zhu

Blood (2022) 140 (Supplement 1): 13214–13215.

https://doi.org/10.1182/blood-2022-164642

Published: 2022

Journal Articles

Update on the Outcome of M-Protein Screening Program of Multiple Myeloma in China: A 7-Year Cohort Study

Wenjing Wang, Jing Li, Yang Yang, Feifei Chen, Tianhong Xu, Pu Wang, Yawen Wang, Aziguli Maihemaiti, Liang Ren, Peng Liu

Blood (2022) 140 (Supplement 1): 10097–10098.

https://doi.org/10.1182/blood-2022-168200

Published: 2022

Journal Articles

MYD88 L265P Mutation and Other Variants Show Different Molecular Characteristics in Diffuse Large B-Cell Lymphoma Treated with R-CHOP in China

Yan Qin, Tian Qiu, Zucheng Xie, Peng Liu, Jianliang Yang, Xiaohui He, Lin Gui, Shengyu Zhou, Hongxin Jiang, Changgong Zhang, Sheng Yang, Le Tang, Yuankai Shi

Blood (2022) 140 (Supplement 1): 9512–9513.

https://doi.org/10.1182/blood-2022-162907

Published: 2022

Journal Articles

Artery Specific Enhancer Is Essential for Specification of Arterial Hemogenic Endothelium with T Lymphoid Potential

Saritha S D'souza, Akhilesh Kumar, Yoon Jung Choi, Samuel T Dettle, Portia Smith, Ho Sun Jung, Peng Liu, Irene Ong, Igor I Slukvin

Blood (2022) 140 (Supplement 1): 8592–8593.

https://doi.org/10.1182/blood-2022-168131

Published: 2022

Journal Articles

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Yan Qin, Tian Qiu, Xinrui Chen, Peng Liu, Jianliang Yang, Xiaohui He, Lin Gui, Shengyu Zhou, Hongxin Jiang, Changgong Zhang, Sheng Yang, Le Tang, Yuankai Shi

Blood (2022) 140 (Supplement 1): 12094–12095.

https://doi.org/10.1182/blood-2022-162307

Published: 2022

NARROW

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

The Mechanism Underlying Lenalidomide-Induced Thrombosis Susceptibility

Clinical Implication of Minimal Residual Disease By Multiparameter Flow Cytometry in Light Chain Amyloidosis

The China Monoclonal Gammopathy Screening Project in First-Degree Relatives of Patients with Multiple Myeloma (CHAPERONE) –a Multicenter Screening Study

Effectiveness and Safety of Orelabrutinib Combined with Rituximab As First-Line Treatment in Marginal Zone Lymphoma

Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Manner

A Comparative Study of Clinical Characteristics, Cytogenetic Abnormalities and Outcomes Among Multiple Myeloma, Primary Light-Chain Amyloidosis and Multiple Myeloma with Concurrent AL Amyloidosis

Genomic Determinants of Hematopoietic Progenitor Sensitivity to Innate Immune Signaling

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Exclusive Benefits of Sustained MRD-Negative in High-Risk Multiple Myeloma

Deletion of the Artery Specific Enhancer Promotes B Cell and Impairs T Cell Development from the Hemogenic Endothelium

Short-Term Follow-up of Blinatumomab in Children with B-Cell Precursor Acute Lymphoblastic Leukemia：Study of a Single Center from China

Update on the Outcome of M-Protein Screening Program of Multiple Myeloma in China: A 7-Year Cohort Study

MYD88 L265P Mutation and Other Variants Show Different Molecular Characteristics in Diffuse Large B-Cell Lymphoma Treated with R-CHOP in China

Artery Specific Enhancer Is Essential for Specification of Arterial Hemogenic Endothelium with T Lymphoid Potential

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only